Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR1313124

— · B

b29e9d89-a702-5004-b387-769c5486add1

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
B
subtype
B

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ESTROGEN_RESPONSE_EARLY+0.560
  • ESTROGEN_RESPONSE_LATE+0.500
  • WNT_BETA_CATENIN_SIGNALING+0.260
  • ANGIOGENESIS+0.250
  • PROTEIN_SECRETION+0.250
  • APICAL_JUNCTION+0.240
  • APICAL_SURFACE+0.200
  • TGF_BETA_SIGNALING+0.200
  • APOPTOSIS+0.180
  • COAGULATION+0.180

Top 10 suppressed

  • ALLOGRAFT_REJECTION-0.560
  • INTERFERON_ALPHA_RESPONSE-0.530
  • INTERFERON_GAMMA_RESPONSE-0.510
  • INFLAMMATORY_RESPONSE-0.410
  • IL6_JAK_STAT3_SIGNALING-0.370
  • COMPLEMENT-0.330
  • E2F_TARGETS-0.270
  • KRAS_SIGNALING_UP-0.260
  • MYC_TARGETS_V2-0.260
  • G2M_CHECKPOINT-0.250

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-AN-A0XO-01A-11R-A109-07
breast-umap@18
—C0.859
2TCGA-A1-A0SE-01A-11R-A084-07
breast-umap@18
—A0.831
3TCGA-BH-A0W4-01A-11R-A109-07
breast-umap@18
—A0.800
4TCGA-A8-A09B-01A-11R-A00Z-07
breast-umap@18
—B0.778
5SRR12696767
melanoma-umap@29
——0.770
620030017.LumA
breast-umap@18
—B0.766
7TCGA-BH-A0H6-01A-21R-A056-07
breast-umap@18
—A0.766
8SRR1313121
breast-umap@18
—B0.764
920050073.LumB
breast-umap@18
—B0.759
10DRR168545
bladder-landscape@3
——0.758

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 29 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ESTROGEN_RESPONSE_EARLY0.560Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.500Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.260Inavolisib— uncovered
ANGIOGENESIS0.250Remibrutinib— uncovered
PROTEIN_SECRETION0.250Remibrutinib— uncovered
APICAL_JUNCTION0.240Inavolisib— uncovered
APICAL_SURFACE0.200Temsirolimus— uncovered
TGF_BETA_SIGNALING0.200Inavolisib— uncovered
APOPTOSIS0.180Idelalisib— uncovered
COAGULATION0.180Binimetinib— uncovered
GLYCOLYSIS0.180Inavolisib— uncovered
HEME_METABOLISM0.180Temsirolimus— uncovered
NOTCH_SIGNALING0.180Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.170Inavolisib— uncovered
UV_RESPONSE_DN0.150Inavolisib— uncovered
MITOTIC_SPINDLE0.140Inavolisib— uncovered
P53_PATHWAY0.140Idelalisib— uncovered
ANDROGEN_RESPONSE0.120Inavolisib— uncovered
HYPOXIA0.110Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.110Inavolisib— uncovered